Recombinant DNA Technology Market is expected to grow at CAGR of 4.9% to reach USD 1.06 trillion during the forecasted period 2022-2030.
The Recombinant DNA Technology Market is expected to reach USD 1.06 trillion by 2030 at 4.9% CAGR during the forecast period 2022-2030. Scientists now have unprecedented control over genetic material thanks to recombinant DNA (rDNA) technology. This has increased its use in a wide range of traditional and unconventional applications. This field has made remarkable progress in the creation of recombinant medications and therapies without the use of human donors in recent years. The commercial success of genetically modified insulin for diabetes therapy is a typical example of this feat. The biotech and pharmaceutical industries are engaged in interpreting the potential of rDNA approaches in many parts of disease management. This is primarily to battle the rising burden of chronic diseases and to keep up with the growing demand for treatments. For instance, in February 2022, VBI Vaccines Inc. obtained good feedback from the European Medicines Agency's Committee for Medicinal Product Use. This opinion was connected to the 3-antigen hepatitis B (HBV) vaccine, PreHevbri, for establishing vaccination to protect against infection caused by the hepatitis B virus in adults. Hepatitis B remains a public health issue in Europe; consequently, this favorable opinion established a meaningful choice for health providers in safeguarding patients from the disease.
COVID-19 Impact Analysis
The COVID-19 pandemic had a favorable impact on the market, owing to the unique recombinant technologies used to create the COVID-19 vaccine. According to a National Center for Biotechnology Information article, novel recombinant technologies will be used in developing the COVID-19 vaccine in November 2020, in addition, to live vector and inactivated viruses. The benefits of recombinant vaccinations include increased response predictability and efficacy.
Recombinant DNA Technology Market Dynamics
Remarkable advancements in the sector to treat life-threatening human disorders such as infectious diseases, diabetes, and cancer are some of the major drivers influencing market growth. Recombinant technology advancements have aided in the development of long-acting therapeutic proteins for medication development, the introduction of gene therapy, and the development of innovative molecular medicine. Positive impact on genetic disease treatment and growing innovations will likely drive market expansion during the forecast period. Leading biopharmaceutical businesses and research institutes strategically work with key manufacturers to create novel therapies based on recombinant DNA technology. Such collaborations are expected to drive worldwide market growth throughout the forecast period.
Increasing strategic collaborations by leading market players to advance recombinant DNA technology are projected to fuel market expansion over the forecast period. Major market participants collaborate strategically with major biopharmaceutical companies and research institutes to develop innovative therapies based on recombinant DNA technologies. Such market-wide strategic collaborations are projected to foster the expansion of the market shortly. For instance, Sanofi Pasteur, the vaccines division of the French multinational pharmaceutical company Sanofi, acquired Protein Sciences Corporation, a biotech company based in Meriden, Connecticut, in August 2017 to add a promising product to its vaccine portfolio - Flublok (Influenza Vaccine), the only FDA-approved recombinant protein-based influenza vaccine.
The high expense of gene therapy and adverse effects such as Cytokine Release Syndrome (CRS) or Neurological Toxicities are inhibiting market expansion. Additionally, scientific, regulatory, and ethical constraints linked with gene therapy are projected to limit market expansion during the projection period.
Many additional businesses benefit from genetically modified organisms (GMO) research, such as microorganisms that are considered clean fuel generators and bio degraders. Genetically engineered vaccinations are produced to cure numerous diseases in humans and plants. By changing microbes, animals, and plants to provide medically valuable compounds, recombinant DNA technology has created various potential opportunities and prospects for generating a wide range of therapeutic items with immediate effects in medical genetics and biomedicine.
Recombinant DNA Technology Market Segmentation
The market segment of recombinant DNA technology, by product, is medical and non-medical. The medical segment dominated the market in 2021, and this trend is expected to continue at the highest CAGR over the forecast period. rDNA technology has changed the medical industry and has an ever-increasing impact on clinical medicine. It has facilitated illness treatment by inserting fresh genes in place of damaged & sick genes. Growth in the medical segment is expected to be also driven by advances in genetic engineering and process development. The success of GM crops is driving the non-medical component of this business.
The market segment of recombinant DNA technology, by component, is expression system and cloning vector. The largest part was acquired by expression systems, owing to continuous improvements for efficient protein expression and large-scale protein isolation. Mammalian, bacterial, insect, and yeast expression systems are the most commonly employed. The creation of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO) has contributed significantly to the mammalian expression system market share.
By application, the market is segmented into food & agriculture and health & disease. The health & disease application has accounted for the majority of the share in the recombinant DNA technology market growth in 2021. This high proportion can be attributable to a diverse variety of recombinant products for human illness treatment, including medicines, vaccines, and enzyme replacements. With the increasing burden of crop development and the resulting stress on farmers to satisfy customer expectations, this technology has steadily grown as a panacea for tackling these agriculture sector concerns.
End User Insights
By end user, the market is segmented into biotechnology companies and pharmaceuticals. The biotechnology companies category dominated the market in 2021. With demand growing in industries including pharmaceutical, healthcare, medicine, genetic engineering, animal husbandry, agriculture, etc., biotechnology companies are burgeoning employment options.
Global Recombinant DNA Technology Market Share, by Region, 2021 (%)
Recombinant DNA Technology Market Overview, by Region
By Region, the market of recombinant DNA technology has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the most extensive market share. Asia-Pacific will exhibit the highest CAGR during the forecast period.
In 2021, the North American region held the largest market share. The greatest proportion of the North American area can be attributable to the fact that the United States is home to many biopharmaceutical manufacturing participants. Furthermore, the availability of strong regulatory organizations to monitor the numerous ethical and scientific concerns associated with using technology has fueled regional progress.
The presence of low-cost manufacturing centers in Asian nations such as China has piqued the interest of multinational companies looking to relocate their operations to this region. Furthermore, Japan is one of the world's tops per capita importers of food and feed, developed with current biotechnology methods. Japan's GE agricultural regulating regime is becoming better. Furthermore, there are no significant trade barriers in Japan to impede the export of GE items from Western countries. As a result, Asia-Pacific is predicted to be the region's fastest-growing market in the forecast period.
Recombinant DNA Technology Market Competitive Landscape
The market includes tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach with diverse product portfolios. Companies such as Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), and Novartis AG (Switzerland) dominate the market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are concentrating on supporting research and development. Furthermore, they embrace strategic growth initiatives, such as development, product introduction, joint ventures, and partnerships, to strengthen their market position and capture an extensive customer base. For instance, VBI Vaccines Inc. approved PreHevbrio (Recombinant Hepatitis B Vaccine) in the United States in March 2022 to prevent infection caused by hepatitis B virus (HBV) in adults aged 18 and older. Furthermore, the release of the vaccine can potentially increase immunization rates with US health professionals' help while protecting adult patients against HBV.
Prominent players in the recombinant DNA technology market research include Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Genscript Biotech (U.S.), Pfizer Inc. (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), and Biogen Inc. (U.S.), among others.
Scope of the Recombinant DNA Technology Market Report
End User Outlook
Objectives of the Study
The objectives of the study are summarized in 5 stages. They are as mentioned below:
Recombinant DNA Technology Market Forecast & Size:
To identify and estimate the market size for the recombinant DNA technology segmented by product, component, application, and end-user by value (in US dollars). Also, to understand the consumption/ demand created by consumers in the market of recombinant DNA technology forecast between 2022 and 2030.
Market Landscape and Trends:
To identify and infer the drivers, restraints, opportunities, and challenges in the recombinant DNA technology market growth
Market Influencing Factors:
To find out the factors which are affecting the market size of recombinant DNA technology among consumers
Impact of COVID-19:
To identify and understand the various factors involved in the market affected by the pandemic
To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company in the past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
|Market Size||USD 1.06 Trillion|
|Forecast Units||Value (USD Trillion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product, Component, Application, and End-User|
|Geographies Covered||North America, Europe, Asia-Pacific, and the Rest of the World (RoW)|
|Key Vendors||Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Novartis AG (Switzerland)|
|Key Market Opportunities||Opportunity in product development|
|Key Market Drivers||Increased R&D initiatives and strategic collaborations among industry participants|
The recombinant DNA technology market forecast period is 2022-2030
The market is expected to register a CAGR of ~4.9% over the next 10 years, according to the recombinant DNA technology market research.
Leading players in the Recombinant DNA Technology Market include Novartis, Profacgen, and Amgen, among others.
Asia-Pacific is expected to register the highest CAGR during 2022-2030
North America held the largest share in 2021
The market size is expected to be USD 1.06 trillion by 2030.
Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), and Biogen Inc. (U.S.) are the major companies operating in the market.